An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Official Title

A Randomized, Multi-centre Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)

Summary:

The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma. NOTE: Global recruitment is complete but enrollment is ongoing for the China sub-study. The Primary Completion Date for ORR will be reached July 2017. The Completion Date for all Primary Outcome Measures is expected in October 2018.

Trial Description

Primary Outcome:

  • Overall Survival (OS)
  • Overall Response Rate (ORR)
Secondary Outcome:
  • Progression-Free Survival (PFS)
  • Programmed death (PD)-L1 expression

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society